| Literature DB >> 23781502 |
A Fernández-Serra1, L Rubio, A Calatrava, J Rubio-Briones, R Salgado, R Gil-Benso, B Espinet, Z García-Casado, J A López-Guerrero.
Abstract
Prostate cancer (PCa) is a very heterogeneous disease, and there are constraints in its current diagnosis. Serum PSA levels, digital rectal examination (DRE), and histopathologic analysis often drive to overdiagnosis and overtreatment. Since 2005, the presence of the genetic rearrangement between transmembrane-serine protease gene (TMPRSS2) and the erythroblast transformation-specific (ETS) member ERG (v-ets erythroblastosis virus E26 oncogene homolog avian) has been demonstrated in almost half of PCa cases. Both FISH and RT-PCR are useful tools for detecting these rearrangements, but very few comparatives between both techniques have been published. In this study, we included FFPE tumors from 294 PCa patients treated with radical prostatectomy with more than 5 years of followup. We constructed a total of 20 tissue microarrays in order to perform break-apart and tricolor probe FISH approaches that were compared with RT-PCR, showing a concordance of 80.6% (P < 0.001). The presence of TMPRSS2-ERG rearrangement was observed in 56.6% of cases. No association between TMPRSS2-ERG status and clinicopathological parameters nor biochemical progression and clinical progression free survival was found. In conclusion, this study demonstrates that both FISH and RT-PCR are useful tools in the assessment of the TMPRSS2-ERG fusion gene status in PCa patients and that this genetic feature per se lacks prognostic value.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23781502 PMCID: PMC3678465 DOI: 10.1155/2013/465179
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographics and main clinical and pathological features of the analyzed series.
| Parameters |
| % |
|---|---|---|
| PSA | ||
| <10 ng/mL | 186 | 63.3 |
| 10–20 ng/mL | 66 | 22.4 |
| >20 ng/mL | 42 | 14.3 |
| Gleason-sp | ||
| ≤6 | 118 | 40.1 |
| 7 | 139 | 47.3 |
| 8–10 | 37 | 12.6 |
| cT | ||
| ≤cT2b | 273 | 92.9 |
| ≥cT3a | 19 | 6.5 |
| pT | ||
| ≤pT2 | 160 | 54.4 |
| ≥pT3 | 133 | 45.2 |
| pN* | ||
| pN0 | 190 | 64.6 |
| pN ≥ 1 | 10 | 3.4 |
| Perineural invasion | ||
| Negative | 126 | 42.7 |
| Positive | 145 | 49.2 |
SP: specimen, cT: clinical stage, pT: pathological stage, PSA: prostatic-specific antigen, and pN: pathologic stage with respect to lymph node status.
*Lymphadenectomy was limited to the obturator fossa in most of the cases at the inclusion period.
Figure 1(a) Patterns obtained in the tricolor probe FISH analysis. Three fused signals indicate two normal alleles (A1); a balanced translocation pattern is considered with a fused (RGB) signal and an adjacent BG with a separated R signals (A2); interstitial deletion is indicated by a RGB signal and a B and R adjacent signals (A3); one RGB signal plus only one R, B, or G signal (A4, A5, A6, resp.) corresponds to undetermined rearrangements. (b) Patterns of the dual color break-apart assay: normal pattern with two RG signals (B1); balanced translocation is indicated by a RG signal plus a G and R separated signals (B2); one RG signal plus a R signal indicates interstitial deletion (B3).
Figure 2Gel electrophoresis showing representative results for the TMPRSS2-ERG gene status determined by RT-PCR. Lane 1: size marker; lines 3, 4, 5, and 8: positive cases showing a PCR product between the bands of 100 and 200 bp of the size marker; lanes 2, 6, and 7 are negative cases, and lane 9 is a negative template control.
Correlation between the mechanism of the rearrangement and the clinical and pathological parameters.
| Parameters |
| Break apart (%) | Interstitial deletion (%) |
|
|---|---|---|---|---|
| PSA | ||||
| <10 ng/mL | 85 (47) | 73 (73) | 23 (23) | |
| 10–20 ng/mL | 29 (45.3) | 29 (45.3) | 6 (9.4) | 0.907 |
| >20 ng/mL | 18 (43.9) | 17 (41.4) | 6 (14.6) | |
| Gleason-sp | ||||
| 2–6 | 56 (49.6) | 45 (39.8) | 12 (10.6) | |
| 7 | 57 (41.9) | 61 (44.9) | 18 (13.2) | 0.693 |
| >7 | 19 (51.4) | 13 (35.1) | 5 (13.5) | |
| cT | ||||
| ≤cT2b | 122 (45.9) | 109 (41) | 23 (23) | 0.251 |
| ≥cT3a | 9 (50) | 9 (50) | 0 (0) | |
| pT | ||||
| ≤pT2 | 75 (48.7) | 60 (39) | 19 (12.3) | 0.639 |
| ≥pT3 | 57 (43.5) | 58 (44.3) | 16 (12.2) | |
| pN* | ||||
| pN0 | 84 (45.4) | 75 (40.5) | 26 (14.1) | 0.177 |
| pN ≥1 | 2 (20) | 7 (70) | 1 (10) | |
| Perineural invasion | ||||
| Negative | 63 (51.2) | 44 (35.8) | 16 (13) |
|
| Positive | 53 (38.1) | 70 (50.4) | 16 (11.5) |
Crosstabs with the parameters of the comparison between RT-PCR and FISH techniques.
| Fish |
| ||
|---|---|---|---|
| Negative | Positive | ||
| RT-PCR | |||
| Negative | 122 (80.2%) | 27 (19%) | <0.001 |
| Positive | 30 (19.7%) | 115 (81%) | |
Correlation between the presence of TMPRSS2-ERG determined by FISH and/or RT-PCR and the CPP.
| Parameters |
|
|
|
|---|---|---|---|
| PSA | |||
| <10 ng/mL | 85 (64.4) | 101 (62.3) | |
| 10–20 ng/mL | 28 (21.2) | 38 (23.5) | 0.899 |
| >20 ng/mL | 19 (14.4) | 23 (14.2) | |
| Gleason-sp | |||
| 2–6 | 50 (37.9) | 68 (42) | |
| 7 | 61 (46.2) | 78 (48.1) | 0.292 |
| >7 | 21 (15.9) | 16 (9.9) | |
| cT | |||
| ≤cT2b | 123 (93.2) | 150 (93.8) | 0.514 |
| ≥cT3a | 9 (6.8) | 10 (6.3) | |
| pT | |||
| ≤pT2 | 74 (56.1) | 86 (53.4) | 0.369 |
| ≥pT3 | 58 (43.9) | 75 (46.6) | |
| pN* | |||
| pN0 | 82 (96.5) | 108 (93.9) | 0.317 |
| pN ≥ 1 | 3 (3.5) | 7 (6.1) | |
| Perineural invasion | |||
| Negative | 61 (51.7) | 65 (42.8) |
|
| Positive | 57 (48.3) | 87 (53.3) |
*Lymphadenectomy was limited to the obturator fossa in most of the cases.
Log-rank and Cox regression tests for BPFS and clinical PFS in the 294 cases analyzed.
| Parameters |
| Biochemical progression | Clinical progression | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events | %BPFS |
| HR | 95% CI |
| Events | % Clinical PFS |
| HR | 95% CI |
| ||
| PSA | |||||||||||||
| ≤10 ng/mL | 186 | 37 | 53.6 | 1 |
| 20 | 77.7 | ||||||
| 10–20 ng/mL | 66 | 26 | 50.4 |
| 2.9 | 1.6–5.3 |
| 18 | 52.3 |
| NS | ||
| >20 ng/mL | 42 | 20 | 28.2 | 1.6 | 0.8–3 |
| 12 | 51.9 | |||||
| Gleason-sp | |||||||||||||
| 2–6 | 118 | 21 | 67.7 | 1 |
| 11 | 78.4 | 1 |
| ||||
| 7 | 139 | 39 | 46.3 |
| 4.4 | 2.2–8.5 |
| 26 | 59 |
| 4.8 | 2–11.1 |
|
| >7 | 37 | 23 | 0 | 3.2 | 1.8–5.7 |
| 13 | 48 | 2.5 | 1.3–5 |
| ||
| cT | |||||||||||||
| ≤cT2b | 274 | 72 | 51.4 |
| NS | 45 | 65.7 | 0.410 | NS | ||||
| ≥cT3a | 19 | 11 | 26.4 | 5 | 65.4 | ||||||||
| pT | |||||||||||||
| ≤pT2 | 161 | 24 | 68.3 |
| NS | 14 | 77.8 |
| NS | ||||
| ≥pT3 | 133 | 59 | 35.4 | 36 | 56.7 | ||||||||
| pN | |||||||||||||
| pN0 | 66 | 125 | 50 |
| 1 |
| 40 | 67.6 |
| NS | |||
| pN ≥ 1 | 9 | 1 | 0 | 2.3 | 1.1–5.1 | 5 | 33.8 | ||||||
| Perineural inv. | |||||||||||||
| Negative | 126 | 24 | 56.9 |
| 1 |
| 13 | 82.9 |
| 1 |
| ||
| Positive | 144 | 58 | 44.7 | 2.4 | 1.4–4 | 36 | 50.8 | 2.3 | 1.2–4.5 | ||||
|
| |||||||||||||
| Negative | 132 | 31 | 58.7 | 18 | 74.3 | ||||||||
| Translocation | 118 | 39 | 39.3 | 0.229 | 24 | 60.1 | 0.380 | ||||||
| Deletion | 35 | 10 | 39.4 | 6 | 72.4 | ||||||||
| Fusion gene status | |||||||||||||
| Negative | 127 | 35 | 51 | 0.824 | 22 | 68 | 0.855 | ||||||
| Positive | 166 | 47 | 48.2 | 26 | 67.7 | ||||||||
SP: specimen, BPFS: biochemical progression free survival, PFS: progression free survival, and NS: not significant.
Figure 3Kaplan-Meier plots of the univariate survival analysis. (a) Biochemical progression free survival (BPFS) according to the TMPRSS2-ERG status measured by FISH and/or RT-PCR. (b) BPFS according to the mechanism of the rearrangement determined by tricolor FISH assay.